Skip to Content


Medically reviewed by Last updated on Oct 13, 2018.


(ten A pa nor)

Index Terms

  • Ibsrela
  • Tenapanor Hydrochloride

Pharmacologic Category

  • Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor

Use: Labeled Indications

Irritable bowel syndrome with constipation: Treatment of irritable bowel syndrome with constipation (IBS-C) in adults.


Patients <6 years of age; known or suspected mechanical GI obstruction

Drug Interactions

There are no known significant interactions.

Adverse Reactions

>10%: Gastrointestinal: Diarrhea (15% to 16%)

1% to 10%:

Central nervous system: Dizziness (2%)

Gastrointestinal: Flatulence (3%), severe diarrhea (3%), abdominal distension (2% to 3%), abnormal bowel sounds (<2%)

Hematologic & oncologic: Rectal hemorrhage (<2%)

ALERT: U.S. Boxed Warning

Risk of serious dehydration in pediatric petients

Tenapanor is contraindicated in patients <6 years; in nonclinical studies in young juvenile rats, administration of tenapanor caused deaths presumed to be due to dehydration; avoid use of tenapanor in patients 6 years to <12 years; the safety and effectiveness of tenapanor have not been established in patients <18 years.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about tenapanor

Consumer resources

Professional resources

Other brands: Ibsrela

Related treatment guides